Semaglutide Research Guide
For laboratory and research use only. Not for human or veterinary use. This page summarizes published scientific literature for educational purposes only.
Semaglutide is the most widely studied molecule in the GLP-1 receptor agonist class and a common reference compound in metabolic research. This guide covers its mechanism, what the published clinical literature reports, and how laboratories characterize and handle it. It is part of our GLP-1 research peptides hub.
What is semaglutide?
Semaglutide is a synthetic analog of the incretin hormone GLP-1, engineered for stability so that it resists rapid breakdown by the DPP-4 enzyme. As a single GLP-1 receptor agonist, it engages one receptor pathway — the GLP-1 receptor — which distinguishes it from dual agonists like tirzepatide and triple agonists like retatrutide.
Mechanism of action
In the published literature, GLP-1 receptor activation is described as producing glucose-dependent insulin secretion, suppression of glucagon release, slowed gastric emptying, and appetite modulation through central nervous system signaling. The “glucose-dependent” quality is frequently noted in the literature as central to the pharmacology of the class.
What the clinical literature reports
Semaglutide as a pharmaceutical drug product has been characterized across two large clinical trial programs conducted by its sponsor: the SUSTAIN program (type 2 diabetes) and the STEP program (weight management), with results published in journals including the New England Journal of Medicine. These trials studied the approved drug product in humans — not research-grade material — and are summarized here only to explain the science. Researchers should consult primary sources on PubMed.
How it compares
Because semaglutide engages a single receptor, it is the baseline against which newer multi-receptor compounds are measured. For a direct comparison with the leading dual agonist, see Semaglutide vs Tirzepatide.
Dosing used in the clinical trials
The following reports the dose regimens administered in published clinical trials of the semaglutide drug product, for scientific context only. It is not a recommendation, a protocol, or guidance for use, and it does not describe how the research-grade material sold here should be used. Self-administering research peptides can be dangerous; these products are strictly for laboratory research.
In the STEP 1 obesity trial (Wilding et al., New England Journal of Medicine, 2021), semaglutide was given once weekly by subcutaneous injection on a fixed escalation schedule — the dose increased every 4 weeks toward a 2.4 mg maintenance dose. The gradual ramp is described in the literature as a way to improve gastrointestinal tolerability.
Semaglutide weekly dose by titration step — STEP 1
At the 2.4 mg maintenance dose, STEP 1 reported a mean body-weight reduction of about 14.9% over 68 weeks. The separate type 2 diabetes program (SUSTAIN) used a lower ceiling — maintenance commonly at 1.0 mg, and up to 2.0 mg in later studies. Sources: STEP 1 (NEJM 2021); FDA prescribing information.
Laboratory handling
Research-grade semaglutide ships as a lyophilized (freeze-dried) powder and is characterized by HPLC, with a Certificate of Analysis available on our Lab Results page. Before use it is reconstituted with sterile bacteriostatic water; our reconstitution calculator returns the exact diluent volume, and the reconstitution guide walks through the procedure. You can view research-grade semaglutide in our catalog; bacteriostatic water is included free with every order.
Frequently asked questions
Is semaglutide a single or dual agonist?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist and retatrutide is a triple GLP-1/GIP/glucagon agonist.
How is research-grade semaglutide characterized?
By HPLC analysis with a third-party Certificate of Analysis documenting identity and purity, typically at ≥99%.
What diluent is used to reconstitute it?
Sterile bacteriostatic water is the standard diluent; the exact volume depends on the vial’s milligram content and the target concentration.
Disclaimer: Research-grade semaglutide supplied by MyGLP1Store is strictly for laboratory and in-vitro research. It is not an approved drug, not a supplement, and not for human or veterinary use. Clinical trial data above pertains to the pharmaceutical drug product studied by its sponsor.